Use of trehalose for treatment of neurological diseases
AssigneeJunaxo, Inc.
InventorsJonathan Michael Brotchie, Patrick Alexander Howson
Life of this patent
Estimating the term…
Loading patent…
AssigneeJunaxo, Inc.
InventorsJonathan Michael Brotchie, Patrick Alexander Howson
Estimating the term…
The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be about 2.67 g/kg/day. A method for treating a neurological disorders is disclosed which involves administering trehalose to a subject as a single daily administration with a daily dose between about 0.25 to about 12.5 g/kg/day and in an embodiment of this method the daily dose is about 2.67 g/kg/day. Also disclosed herein is the use of trehalose in the manufacture of a medicament for treatment of neurological disorders, wherein the trehalose is formulated as a single daily dose with the trehalose present in the medicament in an amount of between about 0.25 to about 12.5 g/kg/day. In an embodiment the daily dose is about 2.67 g/kg/day. The present disclosure provides a pharmaceutical composition for treating neurological disorders, comprising a daily dose of trehalose, and a pharmaceutically acceptable carrier wherein the daily dose of the trehalose is between about 0.25 to about 12.5 g/kg. The trehalose may be formulated as part of a foodstuff.
A method for treating neurological disorders, comprising chronically administering trehalose administered as a single oral daily dose, in a physiologically acceptable carrier wherein the single oral daily dose of the trehalose is between about 1.25 to about 12.5 grams of trehalose per kilogram of body weight of a patient to which said single oral dose is being administered to, wherein the neurological disorders are any one or a combination of Parkinson's disease and synucleinopathies.
A method for treating neurological disorders, comprising administering a single oral daily dose of trehalose in a physiologically acceptable carrier wherein the single oral daily dose of the trehalose is in the following amount in the physiologically acceptable carrier, wherein the neurological disorders are any one or combination of Parkinson's disease and synucleinopathies:
Dependencies are inferred from the claim text.